Journal article 214 views 31 downloads
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Leonardo Buttice 
,
Maryam Ghani,
Janahan Suthakar,
Sathyan Gnanalingham,
Elliott Carande,
Brett W. C. Kennedy,
Alex Pitcher,
James H. P. Gamble ,
Mahmood Ahmad,
Andrew Lewis,
Peter Jüni,
Oliver J. Rider,
Jeffrey Stephens ,
Jonathan J. H. Bray
,
Maryam Ghani,
Janahan Suthakar,
Sathyan Gnanalingham,
Elliott Carande,
Brett W. C. Kennedy,
Alex Pitcher,
James H. P. Gamble ,
Mahmood Ahmad,
Andrew Lewis,
Peter Jüni,
Oliver J. Rider,
Jeffrey Stephens ,
Jonathan J. H. Bray
Diabetes, Obesity and Metabolism
Swansea University Author:
Jeffrey Stephens
-
PDF | Version of Record
© 2024 The Authors. This is an open access article under the terms of the Creative Commons Attribution License.
Download (5.03MB)
DOI (Published version): 10.1111/dom.15586
Abstract
AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammato...
| Published in: | Diabetes, Obesity and Metabolism |
|---|---|
| ISSN: | 1462-8902 1463-1326 |
| Published: |
Wiley
2024
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa66055 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
AimsTo conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.ResultsThirty-eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow-up of 16 (12–24) weeks. Meta-analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin-6, tumour necrosis factor receptor-1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C-reactive protein (CRP), tumour necrosis factor-α, plasminogen activator inhibitor-1, fibroblast growth factor-21 or monocyte chemoattractant protein-1.ConclusionsOur analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP. |
|---|---|
| Keywords: |
cardiovascular disease, dapagliflozin, empagliflozin, inflammation, mechanism of action, sodium-glucose co-transporter-2 inhibitors |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
The authors received no funding. |